Immunohematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Italian National Blood Center, National Institute of Health, Rome, Italy.
Blood Transfus. 2023 Jul;21(4):337-344. doi: 10.2450/2022.0134-22. Epub 2022 Dec 5.
The high safety of homologous blood components, together with the introduction of the Patient Blood Management strategy, has led to the progressive abandonment of preoperative autologous blood donation (PAD) in surgery. Furthermore, recent scientific publications provide evidence about the non-usefulness of PAD in the collection of hematopoietic stem cells (HSC) from bone marrow (BM), also in consideration of harvest procedure safety. Nevertheless, no conclusive studies have been published yet.
Blood Establishments (BE) and Bone Marrow Collection Centers (BMCC) participated in a specific qualitative survey proposed by Italian National Blood and Transplant centers with the support of the relevant Italian Scientific Societies. The survey aimed at evaluating the policy adopted for PAD in related and unrelated adult HSC donors in Italy during the period 2018-2020.
Forty-one BE corresponding to 37 BMCC filled in the questionnaire. Of 830 BM donors, 661 (80%) underwent 1063 PAD (mean 1.6 PAD/donor). The remaining 169 donors (20%) underwent BM harvest without PAD. No serious adverse events were reported for either donor group. In the case of ineligibility of donors for the PAD program, due to low hemoglobin values, 7/10 centers shifted donors to peripheral blood stem cell collection and three centers chose a different donor. Remarkably, only 51% of the PAD units requested were eventually transfused during the BM harvest process. Finally, the iron support policy among centers was heterogeneous.
The results of this survey show that PAD is heterogeneously applied in Italian BMCC, as in other countries. However, all BMCC except two are willing to adopt a Patient Blood Management strategy as an alternative approach to adult related and unrelated BM donor harvests.
同源血液成分的高安全性,加上患者血液管理策略的引入,导致手术中逐步放弃术前自体血采集(PAD)。此外,最近的科学出版物提供了证据,证明 PAD 在从骨髓(BM)采集造血干细胞(HSC)方面没有用处,同时也考虑到采集程序的安全性。然而,目前还没有发表确凿的研究结果。
血液机构(BE)和骨髓采集中心(BMCC)参与了意大利国家血液和移植中心在相关意大利科学协会的支持下提出的一项特定定性调查。该调查旨在评估意大利在 2018-2020 年期间,在相关和无关成人 HSC 供体中采用的 PAD 政策。
41 个 BE 对应 37 个 BMCC 填写了问卷。在 830 名 BM 供体中,661 名(80%)进行了 1063 次 PAD(平均每位供体 1.6 次 PAD)。其余 169 名供体(20%)进行了 BM 采集,而没有进行 PAD。两组供体均未报告严重不良事件。在由于血红蛋白值低而不适合 PAD 计划的情况下,7/10 个中心将供体转移到外周血干细胞采集,3 个中心选择了不同的供体。值得注意的是,只有 51%的 PAD 单位在 BM 采集过程中最终被输血。最后,中心之间的铁支持政策存在差异。
这项调查的结果表明,PAD 在意大利的 BMCC 中应用存在异质性,就像在其他国家一样。然而,除了两个中心之外,所有的 BMCC 都愿意采用患者血液管理策略,作为成人相关和无关 BM 供体采集的替代方法。